2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-157708
    HSD17B13-IN-67 2912457-83-9 98%
    HSD17B13-IN-67 (Compound 677) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-67 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-67
  • HY-157710
    HSD17B13-IN-68 3004660-61-8 98%
    HSD17B13-IN-68 (Compound 16) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-68 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-68
  • HY-157717
    HSD17B13-IN-70 3004660-93-6 98%
    HSD17B13-IN-70 (Compound 39) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-70 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-70
  • HY-157720
    HSD17B13-IN-72 3004661-16-6 98%
    HSD17B13-IN-72 (Compound 62) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-72 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-72
  • HY-157722
    HSD17B13-IN-73 3004661-39-3 98%
    HSD17B13-IN-73 (Compound 85) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-73 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-73
  • HY-157723
    HSD17B13-IN-74 2912458-81-0 98%
    HSD17B13-IN-74 (Compound 760) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-74 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-74
  • HY-157724
    HSD17B13-IN-76 2912459-00-6 98%
    HSD17B13-IN-76 (Compound 773) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-76 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-76
  • HY-157726
    HSD17B13-IN-77 2912459-67-5 98%
    HSD17B13-IN-77 (Compound 808) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of < 0.1 μM for estradiol. HSD17B13-IN-77 can be used for research on liver diseases or metabolic disorders.
    HSD17B13-IN-77
  • HY-157730
    2-Myristyldistearin 57396-99-3 98%
    2-Myristyldistearin (SMS) is a triacylglycerol that contains myristic acid and stearic acid.
    2-Myristyldistearin
  • HY-157732
    1,2-Dimyristoyl-3-palmitoyl-rac-glycerol 60138-13-8 98%
    1,2-Dimyristoyl-3-palmitoyl-rac-glycerol (MMP) is a triacylglycerol that contains myristic acid and palmitic acid.
    1,2-Dimyristoyl-3-palmitoyl-rac-glycerol
  • HY-157779
    TPA-NAC 98%
    TPA-NAC is a nonfluorogenic prodrug by introducing N-acetyl-L-cysteine (NAC) into a conjugated acceptor skeleton. TPA-NAC is capable of fluorogenic selective labeling of HSA.
    TPA-NAC
  • HY-157796
    β2AR agonist 4 98%
    β2AR agonist 4 (compound A19) is a potent and selective β2-Adrenoceptor agonist with an EC50 of 3.7 pM. β2AR agonist 4 suppresses the inflammatory cytokines and leukocytes upregulation and improves lung function in COPD rat model.
    β2AR agonist 4
  • HY-157910
    (±)17(18)-EpETE methyl ester 141339-46-0 98%
    (±)17(18)-EpETE methyl ester is an analog of the eicosapentaenoic acid (EPA) metabolite (±)17(18)-EpETE.
    (±)17(18)-EpETE methyl ester
  • HY-157995
    Dyrk1A-IN-7 98%
    Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC50 value of DYRK1A is 28 nM. For CLK2, Kd is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases.
    Dyrk1A-IN-7
  • HY-158037
    α-Glucosidase-IN-55 98%
    α-Glucosidase-IN-55 (Compound 8g) is an orally active and competitive alpha-glucosidase inhibitor, with IC50 and Ki values of 12.1 and 9.66 µM, respectively. α-Glucosidase-IN-55 can be used for the research into type 2 diabetes mellitus (T2DM) to improve blood sugar control and metabolic health.
    α-Glucosidase-IN-55
  • HY-158056
    URAT1/GLUT9-IN-1 2883011-18-3 98%
    URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC50=2.01 μM) and glucose transporter 9 (GLUT9) (IC50=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research.
    URAT1/GLUT9-IN-1
  • HY-158098
    FGFR1 inhibitor-11 2157482-40-9 98%
    FGFR1 inhibitor-11 (compound 5g) binds to FGFR1, inactivation of its downstream ERK1/2 and IκBα/NF-κB signaling inhibited RANKL-induced osteoclastogenesis. FGFR1 inhibitor-11 has oral bioactivity.
    FGFR1 inhibitor-11
  • HY-158114
    Pentadecanoic acid chloride 17746-08-6 98%
    Pentadecanoic acid chloride is an ester product.
    Pentadecanoic acid chloride
  • HY-158130
    FKBP51-Hsp90-IN-1 433313-64-5 98%
    FKBP51-Hsp90-IN-1 (Compound D10) is a selective inhibitor of the FKBP51-Hsp90 protein-protein interaction, with an IC50 value of 0.1 μM against FKBP51. FKBP51-Hsp90-IN-1 can be used in the research of stress-related diseases, Alzheimer's disease, and metabolic disorders.
    FKBP51-Hsp90-IN-1
  • HY-158160
    LBA-3 2918263-09-7 98%
    LBA-3 is a selective, orally active inhibitor for sodium-coupled citrate transporter SLC13A5, with an IC50 of 67 nM. LBA-3 decreases levels of triglyceride and total cholesterol in oleic and palmitic acid (OPA)-stimulated AML12 cells, PCN-stimulated primary mouse hepatocytes and in mouse models, without detectable toxicity. LBA-3 is blood-brain barrier permeable.
    LBA-3
Cat. No. Product Name / Synonyms Application Reactivity